Chimeric molecule for the treatment of th2-like cytokine mediated disorders
The invention provides uses and methods for alleviating respiratory tract symptoms of allergy, asthma, and of viral, bacterial, fungal and parasitic infections by shifting inappropriate TH2 responses to TH1 responses by administering IL-13 receptor-targeted immunotoxins to the respiratory tract.
1. A method for alleviating a respiratory tract symptom of a T H 2-type cytokine mediated disorder in a mammal, said method comprising contacting an IL-13 receptor-expressing cell in some or all of a respiratory tract of said mammal with a chimeric molecule comprising a toxin moiety and a targeting moiety that specifically binds to an IL-13 receptor.
2. A method of claim 1 , wherein said chimeric molecule is administered intranasally.
3. A method of claim 1 , wherein said chimeric molecule is administered into a lung or a bronchial tree.
4. A method of claim 1 , wherein the targeting moiety is selected from the group consisting of: an anti-IL-13 receptor antibody, a fragment thereof capable of binding an IL-13 receptor, IL-13 or a fragment thereof capable of binding to an IL-13 receptor, and a mutated IL-13 or a fragment thereof capable of binding to an IL-13 receptor.
5. A method of claim 1 , wherein the T H 2-type cytokine mediated disorder alleviated is an allergy, asthma, tuberculosis, parasitic infection, viral infection, bacterial infection, or fungal infection.
6. A method of claim 5 , wherein the T H 2-type cytokine mediated disorder alleviated is asthma.
7. A method of claim 5 , wherein the T H 2-type cytokine mediated disorder alleviated is an allergy.
8. A method of claim 6 , wherein the symptom of asthma alleviated is airway hyperresponsiveness.
9. A method for alleviating a respiratory tract symptom of peribronchial fibrosis response in a mammal, said method comprising contacting an IL-13 receptor-expressing cell in some or all of a respiratory tract of said mammal with a chimeric molecule comprising a toxin moiety and a targeting moiety that specifically binds to an IL-13 receptor, thereby alleviating a symptom of peribronchial fibrosis.
10. The method of claim 9 , wherein said chimeric molecule is administered intranasally.
11. The method of claim 9 , wherein said chimeric molecule is administered into a bronchial tree or lung.
12. The method of claim 9 , wherein said chimeric molecule is an anti-IL-13 receptor antibody, a fragment thereof capable of binding an IL-13 receptor, IL-13 or a fragment thereof capable of binding to an IL-13 receptor, and a mutated IL-13 or a fragment thereof capable of binding to an IL-13 receptor, and said toxin moiety is a mutated Pseudomonas exotoxin A.
13. The method of claim 9 , wherein said chimeric molecule is in a pharmaceutically acceptable carrier.
14. A method for alleviating a respiratory tract symptom of pulmonary fibrosis in a mammal, said method comprising contacting an IL-13 receptor-expressing cell in some or all of a respiratory tract of said mammal with a chimeric molecule comprising a toxin moiety and a targeting moiety that specifically binds to an IL-13 receptor, thereby alleviating a symptom of pulmonary fibrosis.
15. The method of claim 14 , wherein said chimeric molecule is administered intranasally.
16. The method of claim 14 , wherein said chimeric molecule is administered into a bronchial tree or lung.
17. The method of claim 14 , wherein said targeting moiety is an anti-IL-13 receptor antibody, a fragment thereof capable of binding an IL-13 receptor, IL-13 or a fragment thereof capable of binding to an IL-13 receptor, and a mutated IL-13 or a fragment thereof capable of binding to an IL-13 receptor, and said toxin moiety is a mutated Pseudomonas exotoxin A.
18. The method of claim 14 , wherein said chimeric molecule is in a pharmaceutically acceptable carrier.